Pharmaceutical compound
| Combination of | |
|---|---|
| Olmesartan | Angiotensin II antagonist |
| Hydrochlorothiazide | Thiazide diuretic |
| Clinical data | |
| Trade names | Benicar HCT, Benitec H, others |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| KEGG | |
Olmesartan/hydrochlorothiazide, sold under the brand name Benicar HCT among others, is a fixed-dose combination medication used to treat high blood pressure. It is a combination of olmesartan medoxomil, an angiotensin II receptor blocker and hydrochlorothiazide, a diuretic. It may be used if olmesartan is not sufficient to manage blood pressure. It is taken by mouth.
Common side effects include nausea, dizziness, and upper respiratory tract infections. Serious side effects may include kidney problems, allergic reactions, electrolyte problems and low blood pressure. Use in pregnancy is not recommended. Olmesartan works by blocking the effects of angiotensin II while hydrochlorothiazide works by increasing the loss of sodium by the kidneys.
No generic version is available in the United States as of 2017. In 2022, it was the 235th most commonly prescribed medication in the United States, with more than 1 million prescriptions.
References
- ^ "Benicar HCT- olmesartan medoxomil-hydrochlorothiazide tablet, film coated". DailyMed. 7 September 2022. Retrieved 3 January 2023.
- ^ Bope ET, Kellerman RD (2016). Conn's Current Therapy 2017 E-Book. Elsevier Health Sciences. p. 124. ISBN 9780323443357.
- ^ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 177–178. ISBN 9780857113382.
- "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
- "Hydrochlorothiazide; Olmesartan Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
